Functional assessment of ABCG2 (BCRP) gene polymorphisms to protein expression in human placenta

被引:224
作者
Kobayashi, D
Ieiri, I
Hirota, T
Takane, H
Maegawa, S
Kigawa, J
Suzuki, H
Nanba, E
Oshimura, M
Terakawa, N
Otsubo, K
Mine, K
Sugiyama, Y
机构
[1] Tottori Univ, Fac Med, Dept Hosp Pharm, Yonago, Tottori 6838504, Japan
[2] Kyushu Univ, Grad Sch Pharmaceut Sci, Dept Clin Pharmacol, Fukuoka 812, Japan
[3] Kyushu Univ, Grad Sch Pharmaceut Sci, Dept Clin Pharmacokinet, Fukuoka 812, Japan
[4] Tottori Univ, Fac Med, Dept Obstet & Gynecol, Div Funct Gen,Res Ctr Biosci & Technol, Yonago, Tottori 6838504, Japan
[5] Tottori Univ, Grad Sch Med Sci, Dept Biomed Sci, Inst Regenerat Med & Biofunct, Yonago, Tottori 6838504, Japan
[6] Univ Tokyo, Grad Sch Pharmaceut Sci, Tokyo, Japan
关键词
D O I
10.1124/dmd.104.001628
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The aim of the present study was to assess the contribution of polymorphisms in the breast cancer resistance protein/ATP-binding cassette transporter G2 (BCRP/ABCG2) gene to the placental expression from a new perspective, allelic imbalance. Polymorphisms were screened by polymerase chain reaction (PCR)-single-strand conformation polymorphism analysis followed by sequencing with DNA extracted from 100 placentas. To examine whether polymorphisms of the BCRP gene correlate with the placental BCRP expression, we determined mRNA and protein levels by quantitative real-time PCR and Western blotting, respectively. In placentas, G34A (Val(12)Met) and C421A (Gln(141)Lys) were frequently observed (18-36%), but C376T, which creates a stop codon (Gln(126) stop codon), was found with an allelic frequency of 1%. The mean of the BCRP protein level was significantly lower (p < 0.05) in homozygotes for the A421 allele than in those for the C421 allele, and heterozygotes had an intermediate value. To evaluate whether the C421A polymorphism acts as a cis-element in BCRP transcription, allelic imbalance was determined using informative lymphoblasts and 56 samples of placental cDNA. In most of the placental samples we tested, the difference in expression levels between the two alleles was small, and only two samples indicated a monoallelic expression (i.e., preferential expression of one allele). These results suggest that 1) the predominant allelic expression pattern of BCRP in placental samples is biallelic, and 2) the mutation C421A is not a genetic variant acting in cis, but is considered to influence the translation efficiency.
引用
收藏
页码:94 / 101
页数:8
相关论文
共 37 条
[1]  
Allen JD, 2002, CANCER RES, V62, P2294
[2]  
Allen JD, 1999, CANCER RES, V59, P4237
[3]  
Allikmets R, 1998, CANCER RES, V58, P5337
[4]   Genetic variation in the ATP-binding Cassette Transporter gene ABCG2 (BCRP) in a Swedish population [J].
Bäckström, G ;
Taipalensuu, J ;
Melhus, H ;
Brändström, H ;
Svensson, AC ;
Artursson, P ;
Kindmark, A .
EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES, 2003, 18 (05) :359-364
[5]   Promoter characterization and genomic organization of the human breast cancer resistance protein (ATP-binding cassette transporter G2) gene [J].
Bailey-Dell, KJ ;
Hassel, B ;
Doyle, LA ;
Ross, DD .
BIOCHIMICA ET BIOPHYSICA ACTA-GENE STRUCTURE AND EXPRESSION, 2001, 1520 (03) :234-241
[6]   Mechanisms of genomic imprinting [J].
Brannan, CI ;
Bartolomei, MS .
CURRENT OPINION IN GENETICS & DEVELOPMENT, 1999, 9 (02) :164-170
[7]   Cis-acting variation in the expression of a high proportion of genes in human brain [J].
Bray, NJ ;
Buckland, PR ;
Owen, MJ ;
O'Donovan, MC .
HUMAN GENETICS, 2003, 113 (02) :149-153
[8]   Imprinting mechanisms [J].
Constancia, M ;
Pickard, B ;
Kelsey, G ;
Reik, W .
GENOME RESEARCH, 1998, 8 (09) :881-900
[9]   ABCG2 pharmacogenetics: Ethnic differences in allele frequency and assessment of influence on irinotecan disposition [J].
de Jong, FA ;
Marsh, S ;
Mathijssen, RHJ ;
King, C ;
Verweij, J ;
Sparreboom, A ;
McLeod, HL .
CLINICAL CANCER RESEARCH, 2004, 10 (17) :5889-5894
[10]   Multidrug resistance mediated by the breast cancer resistance protein BCRP (ABCG2) [J].
Doyle, LA ;
Ross, DD .
ONCOGENE, 2003, 22 (47) :7340-7358